Corbus Pharmaceuticals (CRBP) investor relations material

Executive summary

• Focused on developing therapies in oncology and obesity, with lead programs CRB-701 (Nectin-4 ADC for cancer) and CRB-913 (CB1 inverse agonist for obesity); CRB-701 has FDA Fast Track for HNSCC and cervical cancer, with registrational studies set for summer 2026.

• CRB-701 is in Phase 1/2 trials, with updated data presented at ASCO 2026; CRB-913 completed Phase 1b enrollment (n=240) with topline data expected summer 2026.

• Former CRB-601 program deprioritized after Phase 1 completion.

Financial highlights

• Net loss for Q1 2026 was $23.0 million, compared to $17.0 million in Q1 2025; net loss per share was $1.23, down from $1.39.

• Operating expenses rose to $24.3 million from $19.8 million year-over-year, mainly due to increased R&D and clinical development costs.

• Cash, cash equivalents, and investments totaled $138.2 million as of March 31, 2026, expected to fund operations for at least 12 months and potentially into 2028.

• No revenue generated from product sales; accumulated deficit reached $578.4 million.

Outlook and guidance

• Cash and investments expected to fund operations for at least 12 months from report issuance, with some guidance suggesting runway into 2028.

• Additional capital will be required for continued clinical development and operations.

• Registrational study for CRB-701 in HNSCC planned for summer 2026; CRB-913 Phase 1b topline data expected summer 2026; combination data for CRB-701 + Keytruda in 1L HNSCC expected early Q1 2027.